Gemcitabine and Cisplatin for patients with metastatic or recurrent esophageal carcinoma: A Southwest Oncology Group study

Investigational New Drugs

Volumn 22, Issue 1, 2004, Pages 91-97

  Urba, Susan G ^a,g   Chansky, Kari ^b   Van Veldhuizen, Peter J ^c   Pluenneke, Robert E ^d   Benedetti, Jacqueline K ^b   Macdonald, John S ^e   Abbruzzese, James L ^f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d Kansas City Community Clinical Oncology Program   (United States)

^e ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chemotherapy; Cisplatin; Esophageal cancer; Gemcitabine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HEARING LOSS; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 1042291305     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000006179.20974.af     Document Type: Article

References (21)

1. Panettiere FJ, Leichman LP, Tilchen E, Chen TT: Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: Final report on a Southwest Oncology Group study. Cancer Treat Rep 68: 1023-1024, 1984
2. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Han RG: Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group Experience. Cancer 46: 2149-2153, 1980
3. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091, 1994
4. Coia L: The use of Mitomycin-C in esophageal cancer. Oncol (suppl) 50: 53-62, 1993
5. Kambe M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Yoshino M, Shimada Y, Taguchi T: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 12: 584, 1993
6. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA: Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 20: 95-99, 2002
7. Ilson DH, Saltz L, Enzinger P, Huang Y, Komblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen D: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270-3275, 1999
8. Macdonald JS, Jacobsen JL, Ketchel SJ, Weiss G, Taylor S, Mills G, Kuebler JP, Rivkin S, Conrad M: A phase II trial of topotecan in esophageal cancer: A Southwest Oncology Group study (SWOG 9339). Invest New Drugs 18: 199-202, 2000
9. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′ -difluoro-2′-deoxycytidine). Can Res 50 (14): 4417-4422, 1990
10. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 supp 11: 72-79, 1995
11. Bergman A, Ruiz van Haperen VWT. Weerman G, Kuiper CM, Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Can Res 2: 521-530, 1996
12. Abbruzzese JL, Frost P: Studies on the mechanism of the synergistic interaction between 2′deoxy-5-azacytidine and cisplatin. Can Chem Pharm 30: 31-36, 1992
13. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T: Randomized phase II study of cisplatin and 5-fluorouracil versus cisplatin alone in advanced squamous cell esophageal cancer. Eur J Cancer 33: 1216-1220, 1997
14. van der Gaast, Kok TC, Kerkhofs L, Siersema PD, Tilanus HW, Splinter TA: Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. B J Cancer 80: 1052-1057, 1999
15. van der Gaast A, Polee M, Kok TC, Splinter TAW: Phase I study with weekly cisplatin and increasing doses of paclitaxel in patients with esophageal cancer. Proc Am Soc Clin Oncol 18: 1162, 1999
16. Ilson DH, Ajani J, Bhalla, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834, 1998
17. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen D: A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6: 316-323, 2000
18. Sandler AB, Kindler HL, Einhom LH, Mitchell E, Masters G, Kraut M, Nicol S, Raghavan D: Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 11: 1161-1164, 2000
19. Pipp M, Mulkerin D, Warren D, Hotchkis W, Berlin J, Thomas JP: A phase II trial of gemcitabine and 5-fluorouracil in advanced esophageal cancer. Proc Am Soc Clin Oncol 20: 630, 2001
20. Fleming DR, Glisson SD, Bhupalam L, Michelson GD, Goldsmith GH, LaRocca RV: Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. Am J Clin Oncol 23: 349-352, 2000
21. Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM, van Groeningen CJ: Gemcitabine-cisplatin: A schedule finding study. Ann Oncol 10: 1503-1510, 1999